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Despite changes in the epidemiology of respiratory bacteriol-
ogy among adults with cystic fibrosis (CF), Pseudomonas
aeruginosa remains the most common chronic lung pathogen
[1]. P. aeruginosa status is important in CF because it influ-
ences clinical segregation decisions, choices of preventative
inhaled therapy as well as the choice of antibiotics to treat
pulmonary exacerbations [2–4]. However, there is currently
no Bgold standard^ to define P. aeruginosa status in CF. The
Leeds criteria are commonly used in CF research settings [2].
This set of criteria is highly specific in identifying chronic P.
aeruginosa infection but lack sensitivity when compared
against polymerase chain reaction (PCR) techniques, with a
tendency to under-diagnose chronic P. aeruginosa infection as
intermittent infection [5, 6]. Not surprisingly, clinical trials
evaluating treatments specifically for adults with chronic P.
aeruginosa infection generally avoided using the Leeds
criteria as part of the eligibility criteria. Instead, a myriad of
different definitions are used. For example, the trial evaluating
Ciprofloxacin dry powder inhaler used BA positive sputum or
throat swab culture for P. aeruginosa within the previous 12
months^ as one of the eligibility criteria [7], whilst the
Aztreonam nebuliser trial used BPA-positive sputum culture
within the previous 3 months^ [8].
The Leeds criteria were developed in a paediatric popula-
tion whereby chronic P. aeruginosa is not particularly com-
mon [9] and P. aeruginosa status is still quite fluctuant. Avery
specific test for chronic P. aeruginosa infection, such as the
Leeds criteria, works well in a paediatric population. In an
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adult population, chronic P. aeruginosa infection becomes
much more likely [9] and sensitivity of the chronic P.
aeruginosa definition becomes increasingly important.
Indeed, a previous study found weaker relationships between
health outcomes with P. aeruginosa status according to the
Leeds criteria among adults compared to a paediatric popula-
tion [10].
In our previous study to understand how clinicians across
three specialist adult CF centres in the UK decide on P.
aeruginosa status [11], there was consistency in decision-
making by clinicians across different centres but clinicians
did not always agree with the Leeds criteria. Where there
was disagreement, clinicians tended to diagnose chronic P.
aeruginosa infection when the Leeds criteria did not, because
clinicians assimilated other relevant information (e.g. propor-
tion of negative cough swabs, information on strain typing) in
their decision-making. These results highlight the limitations
of the Leeds criteria in defining P. aeruginosa status among
adults with CF and suggest that a consensus definition for
chronic P. aeruginosa infection that moves beyond solely de-
pending on standard microbiological results will be useful.
Indeed, the challenge of determining P. aeruginosa status in
CF has clear parallels with the challenge of diagnosing pul-
monary exacerbations. Standardised criteria, e.g. the Fuchs’
and EPIC criteria may not be a Bgold standard^ [12, 13], but
these criteria nonetheless allow exacerbations to be diagnosed
with validity as an endpoint in multi-centre clinical trials. Of
note, both the Fuchs’ and EPIC criteria consist of a mixture of
Bobjective^ (e.g. acute FEV1 decline) and Bsubjective^ criteria
(e.g. change in respiratory symptoms) [12, 13], which again
suggests a pragmatic set of chronic P. aeruginosa definition
should include other relevant clinical information that causes
clinicians to disagree with the Leeds criteria.
We therefore built on our previous work by integrating the
expertise of clinicians from a greater number of specialist
adult centres and using a formal consensus method (nominal
group technique [14, 15]) to explicitly develop a pragmatic set
of criteria for defining chronic P. aeruginosa infection among
adults with CF that can be applied clinically and in multi-
centre trials. This work was conducted in parallel to the
CFHealthHub RCT (ISRCTN55504164), with the intention
of using the consensus criteria for this RCT. Clinicians collab-
orating in the RCT were invited, and ten clinicians across
seven adult CF centres in the UK completed all three rounds
of the consensus exercise between August and October 2017.
The final six consensus statements to define chronic P.
aeruginosa infection are summarised in Table 1.
This consensus definition of chronic P. aeruginosa infec-
tion is unique in that it encompasses a number of components
including the number of positive respiratory samples, anti- P.
aeruginosa IgG antibody levels, VNTR typing/genotyping
and clinical context (e.g. types of respiratory samples collect-
ed and potential reasons for suppressed P. aeruginosa growth
due to treatment factors). In contrast, currently available
criteria for chronic P. aeruginosa infection typically only con-
sist of Bone component,^ e.g. the Leeds criteria [2], the
European consensus criteria [16] and the UK CF registry def-
inition [17] only consider the proportion/number of positive
respiratory cultures. This consensus definition provides a
pragmatic and standardised way of using information avail-
able in routine clinical practice to achieve a more sensitive
diagnosis of chronic P. aeruginosa infection among adults
with CF. As previously discussed [11], this consensus defini-
tion could be utilised to select the appropriate participants for
CF clinical trials, help streamline the calculation of
Bnormative adherence^ [18] and guide CF management (es-
pecially the decision to initiate long-term inhaled antibiotics).
Such a multi-component definition of chronic P.
aeruginosa infection means that the data collection process
Table 1 The final six consensus statements to define chronic P.
aeruginosa infection among adults with CF
BMajor criteria^ statements (any one finding alone establishes the
diagnosis of chronic P. aeruginosa infection)
1. ≥ 3 respiratory samples positive for P. aeruginosa in the preceding
1 year, excluding samples collected during a recognised Pseudomonas
eradication course (multiple positive samples within the same calendar
month can only be counted once).
2. ≥ 2 respiratory samples at least 3 months apart positive for P.
aeruginosa in the preceding 1 year, excluding samples collected
during a recognised Pseudomonas eradication course, among people
who predominantly provide cough swabs (i.e. provide more cough
swabs than sputum samples)
BMinor criteria^ statements (any two findings are required to establish the
diagnosis of chronic P. aeruginosa infection)
1. In the preceding 1 year; ≥ 1 respiratory sample positive for P.
aeruginosa (excluding respiratory samples collected during a
recognised Pseudomonas eradication course) AND/OR a strongly
positive (e.g. > 5 ELISA unit or > 2 OD unit) serum Pseudomonas IgG
antibody level, or a trend of rising Pseudomonas IgG antibody levels
(excluding serology samples collected during a recognised
Pseudomonas eradication course)
2. Insufficient number of respiratory samples positive forP. aeruginosa
to fulfil the major criteria in a person with CF who is using long-term
inhaled anti-pseudomonal antibiotic(s) {inhaled antibiotics prescribed
for longer than 3 months are considered Blong-term therapy^}
3. ≥ 2 respiratory samples at least 6 months apart positive for P.
aeruginosa of the same type (VNTR typing / genotyping) AND/OR a
transmissible P. aeruginosa strain (e.g. Liverpool epidemic strain,
Manchester epidemic strain or Midlands1 strain)
4. A person who fulfilled the criteria for chronic P. aeruginosa
infection in the previous year but did not provide adequate number of
negative respiratory samples in the current year {That is to say the
person did NOT provide any of the following: (a) at least × 1 negative
BAL sample OR (b) at least ×4 negative sputum cultures OR (c) at least
× 6 negative respiratory samples of any kind, for example this might
comprise of × 1 negative sputum sample and × 5 negative cough
swabs. Note that multiple negative samples within the same calendar
month can only be counted once and negative samples in a calendar
month with any positive sample cannot be counted.}
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to operationalise the definition would be more complex. Data
for other investigation results and clinical context must be
collected, instead of just collecting data on respiratory sam-
ples. The consensus definition does have a clear structure, so
the required data collection steps can be summarised in a flow
diagram to operationalise the definition with fidelity. An ex-
ample of such a flow diagram is attached as an online
supplement.
The consensus definition is perhaps most sensitive if ade-
quate numbers of respiratory samples are collected, and in
settings with a clear pathway for regular testing of anti-P.
aeruginosa IgG antibody levels and VNTR typing/genotyp-
ing. Guidelines from the US, UK and Europe recommend that
an adult with CF should be reviewed at least 3-monthly, with
respiratory samples collected during each review [19–21].
Current care guidelines do not specify the access and frequen-
cy of anti-P. aeruginosa IgG antibody levels and VNTR
typing/genotyping; hence, these tests may not be universally
available. The consensus definition could still be applied with-
out results of anti-P. aeruginosa IgG antibody levels and
VNTR typing/genotyping, by considering those criteria to be
absent.
Additional work is required to further enhance the consen-
sus definition. This consensus exercise involved a relatively
small group of clinicians in a single country (although the
number of participants is appropriate for the nominal group
technique [22]); hence, future research should seek a broader
participation in the consensus process, e.g. from other CF
health professionals such as microbiologists, and also interna-
tional opinions. Our ability to successfully complete this ex-
ercise over a short time period with minimal resources sug-
gests that similar consensus exercise will be practical in the
future. Further consensus exercises would also allow the def-
inition to evolve in response to additional investigational
methods that may become routinely available in the future.
Data collected during the CFHealthHub RCT could be used
to apply, evaluate and subsequently refine the method to
operationalise the consensus definition. Other empirical data
are also needed to understand the performance of the consen-
sus definition in different settings.
In summary, the proposed consensus definition starts to
address a gap in the current methods of diagnosing chronic
P. aeruginosa infection among adults with CF by using rou-
tinely available investigational tools. Future research should
attempt to refine the consensus definition by seeking opinion
from clinicians outside the CFHealthHub group and using
empirical data for evaluation.
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